Form 4: Director and 10% Owner Boosts DiaMedica Stake

DiaMedica Therapeutics director and 10% owner Jan Stahlberg, through Trill AB, significantly increased his beneficial ownership of common shares in August 2025.

Summary

• Jan Stahlberg, a Director and 10% owner of DiaMedica Therapeutics Inc. (DMAC), through Trill AB, acquired a total of 999,000 common shares in multiple transactions during August 2025.
• The purchases occurred between August 13, 2025, and August 27, 2025, at prices ranging from $5.8573 to $6.00 per share.
• The total value of the acquired shares is approximately $5,958,920.3.
• Following these transactions, Jan Stahlberg, through Trill AB, beneficially owns a total of 7,764,465 common shares.
• Jan Stahlberg has sole power to vote and dispose of these shares, held indirectly through Trill AB, where he is the board member and sole owner.

Sentiment

Score: 9

Explanation: The significant and repeated purchases of common shares by a director and 10% owner indicate a very strong positive sentiment and belief in the company's value and future prospects.

Positives

• Significant insider buying by a director and 10% owner signals strong confidence in the company's future prospects and valuation.
• The substantial increase in beneficial ownership by a key insider can be viewed as a positive indicator for other investors.

Future Outlook

This filing does not contain forward-looking statements or guidance from the company.

Industry Context

Insider buying, particularly by a director and significant shareholder, is often interpreted as a strong vote of confidence in the company's future performance and strategic direction. In the biotechnology sector, where companies like DiaMedica Therapeutics Inc. rely heavily on R&D and clinical trial success, such a move can signal optimism regarding upcoming milestones or the long-term value of their pipeline.

Related Party Transactions

• Jan Stahlberg, a director and 10% owner, indirectly acquired shares through Trill AB, an entity he solely owns and controls. This constitutes a related party transaction as defined by SEC regulations.

Stakeholder Impact

• Shareholders may view the significant insider buying as a positive signal, potentially increasing investor confidence and demand for the stock.
• The increased stake by a director could align management and shareholder interests more closely.

Key Dates

Recommendation

The substantial and consistent insider buying by a director and 10% owner, Jan Stahlberg, through Trill AB, at an aggregate value of nearly $6 million, represents a powerful vote of confidence in DiaMedica Therapeutics Inc. This level of commitment from a key insider suggests a strong belief in the company's intrinsic value and future growth potential, making it a compelling 'strong buy' signal for seasoned investors.

Keywords

DiaMedica Therapeutics, DMAC, Jan Stahlberg, Trill AB, Insider Buying, Share Purchase, Beneficial Ownership, Form 4, Biotechnology, Pharmaceuticals